Current and emerging paradigms in the therapeutic management of atherosclerosis.
BACKGROUND
The pathogenesis of atherosclerosis lies in abnormalities in lipoprotein metabolism leading to pathological interactions with vessel walls and the release of inflammatory components, which further aggravate the disease condition.


OBJECTIVE
To elucidate current and emerging trends in drug discovery towards the development of new entities regulating lipoprotein metabolism and inflammatory components to combat the progression of atherosclerosis.


METHODS
Research/review articles in the public domain and press releases were employed.


CONCLUSIONS
With the recent failure of torcetrapib and succinobucol, drug discovery and development efforts towards the treatment of atherosclerosis have received a big jolt and have been slowed down to a certain extent [corrected]. But this could be a starting point for several new mechanisms that are emerging to discover new drugs to combat the disease.
Tiwari
Atul
A
Jubilant Biosys Ltd., CardioMetabolic Disorder Group, Drug Discovery Unit-Biology, #96, 2nd Stage, Industrial Suburb, Yeshwantpur, Bangalore-560022, Karnatka, India. atul_tiwari@jubilantbiosys.com
D050197:Atherosclerosis / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*
D000960:Hypolipidemic Agents